Trial: 201711181

ACNS1422 – A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Phase

II

Principal Investigator

Cluster, Andrew

Disease Site

Brain and Nervous System

Learn more about this study at: clinicaltrials.gov